BRAF and cancer: Cancer cells bearing the B-raf gene mutation have been reported to exhibit resistance to EGFR inhibitors, and ES-2 cells carry this mutation [27]; therefore, we assumed that the ES-2 cells were resistant to the EGFR inhibitors.